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Background: Dipeptidyl peptidase 4 (DPP4) inhibitors are very useful for the treatment of type 2 diabetes, especially
to patients undergoing hemodialysis (HD). The main action of DPP4 inhibitors is to increase the concentration of
incretin which stimulate the insulin secretion from pancreatic beta cells. Recently, the extra-pancreatic actions of
DPP4 inhibitors were suggested by many reports; a study has shown that hematopoiesis in mice after radiation
or chemotherapy was enhanced receiving an oral DPP4 inhibitor sitagliptin. It suggests the possibility that DPP4
inhibitors can reduce the dosage of erythropoiesis-stimulating agents (ESAs) in HD patients. But there is no clinical
report about the effect of DPP4 inhibitors on renal anemia in HD patients. This study was designed to confirm the
clinical effect of DPP4 inhibitors on the reduction of dosage of ESA or improvement of renal anemia.
Methods: Over a 6-month period from October 2013 to June 2014, a daily dose of DPP4 inhibitor linagliptin (5 mg/
day) was administered orally to 25 patients on HD who were diagnosed with diabetes mellitus in our institution. The
dosage of ESA darbepoetin alfa (DA), ESA-resistant index (ERI: DA dosage/hemoglobin), hemoglobin concentration,
transferring saturation (TSAT), ferritin, and high-sensitivity C-reactive protein (hs-CRP) were measured and averaged for
3 months before and after the treatment.
Results: At the end of the 6 months, 12 patients were excluded from the analysis due to death, hospitalization in
another hospital, cancer, or withdrawal. After administration of linagliptin, the dosage of DA and ERI decreased
significantly (P < 0.05, paired t test).The dosage of DA decreased from a mean ± SD of 23.9 ± 21.2 to 11.3 ± 9.7
(μg/week), and ERI decreased from 2.3 ± 2.1 to 1.0 ± 0.9. Hemoglobin concentration, white blood cell (WBC) count,
platelet count, ferritin, and TSAT level were not different. Hs-CRP, as the marker of inflammation, was not different, too.
Conclusions: This study suggests that DPP4 inhibitor linagliptin can decrease the dosage of ESA without the influence
of iron metabolism and inflammation. The previous study has shown that DPP4 cleaves within N-terminal of
erythropoietin and decreases their activity in mice. We speculate that DPP4 inhibitors can increase the concentration of
erythropoietin by inhibiting this action of DPP4.Background
Dipeptidyl peptidase 4 (DPP4) inhibitors are very
useful for the treatment of patients with type 2
diabetes mellitus (T2DM), especially those undergo-
ing hemodialysis in Japan. Other glucose-lowering
agents, such as sulfonylureas, biguanides, thiazolidi-
nediones, and nateglinide (an ultrafast-acting insulin* Correspondence: masaki-aono@satohp.co.jp
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in Japan [1].
DPP4 inhibitors selectively block DPP4, increase the
activity of glucagon-like peptide-1 (GLP-1), stimulate in-
sulin secretion, and inhibit glucagon secretion. Recently,
the extra-pancreatic actions of DPP4 inhibitors have
been indicated by many reports, including kidney and
cardiovascular protection, among other effects [2–5].
DPP4 is a protease that cleaves to selected amino acids
in the penultimate N-terminal position and has thele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Demographic characteristics before treatment
DPP4+ DPP4− P
N 13 16
Age 70.5 ± 12.4 71.7 ± 10.2 NS
Male 8 11 NS
BMI 21.7 ± 3.1 22.6 ± 4.1 NS
HD duration 6.5 ± 5.5 10.4 ± 6.2 NS
Hb 10.8 ± 0.6 11.0 ± 0.8 NS
Dosage of DA 23.9 ± 21.2 16.1 ± 12.1 NS
ERI 2.28 ± 2.08 1.52 ± 1.19 NS
Albumin 3.6 ± 0.4 3.5 ± 0.3 NS
TSAT 24.2 ± 6.6 28.9 ± 13.5 NS
Ferritin 264.7 ± 334.6 138.8 ± 137.3 NS
hs-CRP 5335 ± 6494 4345 ± 9372 NS
GA 22.1 ± 5.8 25.2 ± 5.8 NS
DA darbepoetin alfa, ERI erythropoiesis-stimulating agent-resistant index,
Hb hemoglobin, TSAT transferrin saturation, BMI body mass index, GA glycated
albumin
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DPP4 cleaves to the N-termini of factors such as the
colony-stimulating factor (CSF), granulocyte-macrophage
(GM)-CSF, G-CSF, interleukin-3, and erythropoietin and
can decrease their activity [7]. Both in vitro and in vivo,
DPP4 knockout or DPP4 inhibition enhanced CSF activ-
ities [7]. In mice undergoing radiation or chemotherapy,
hematopoiesis was enhanced after receiving the oral DPP4
inhibitor sitagliptin. That study suggested that DPP4
inhibitors can reduce the dosage of erythropoiesis-
stimulating agents (ESAs) required for patients undergo-
ing hemodialysis. However, presently, no clinical reports
have assessed the effect of DPP4 inhibitors on renal
anemia in patients with T2DM undergoing hemodialysis.
The aim of our study was to evaluate whether DPP4 in-
hibitors reduced ESA dosage or contributed to the im-
provement of renal anemia in Japanese patients with
T2DM undergoing hemodialysis.
Methods
Study design and participants
The present study was a cohort study including patients
with T2DM undergoing hemodialysis at the Sato
Junkanki Hospital in Matsuyama, Japan, between Octo-
ber 2013 and June 2014. We divided the patients into
two groups for comparison: one group received DPP4
inhibitor (DPP4+ group) and the other did not receive
DPP4 inhibitor (DPP4− group).
A daily dose of DPP4 inhibitor linagliptin (5 mg/day)
was administered orally to 25 patients diagnosed with
T2DM on hemodialysis (DPP4+ group). At the end of
the 6 months of treatment, 12 patients were excluded
from the analysis because of death, transfer to another
hospital, cancer, or withdrawal. Thus, data of 13 patients
in the DPP4+ group were included in the analysis. A
total of 16 patients were only treated by subcutaneous
insulin injection and did not receive DPP4 inhibitor lina-
gliptin (DPP4− group). As a result, a total number of 29
patients were included in the analysis.
The administration of linagliptin was decided case-by-
case, as there are currently no clear criteria for the use
of linagliptin. The only treatments administered in this
study were linagliptin as a DPP4 inhibitor and darbepoe-
tin alfa (DA) as an ESA, except for the treatment of DM.
The study was approved by the Ethics Committees of
Sato Junkanki Hospital. All the participants gave written
informed consent.
Clinical measures
Clinical measures obtained before and after treatment
included age, sex, hemodialysis duration, hemoglobin,
transferring saturation (TSAT), ferritin, high-sensitivity
C-reactive protein (hs-CRP), and serum glycated albu-
min. The dosage of ESA DA, ESA-resistant index (ERI:DA dosage/hemoglobin), hemoglobin concentration,
TSAT, ferritin, and hs-CRP were measured and averaged
3 months before and 3 months after the treatment.
The dosage of DA was adjusted to maintain a
hemoglobin concentration between 10 and 12 g/dl ac-
cording to the guidelines of the Japanese Society for Dia-
lysis Therapy.Statistical analysis
Statistical analyses of data were performed using Statis-
tical Package for the Social Sciences (SPSS Inc., Chicago,
IL, USA) for Windows version 17.0. Mann–Whitney U
test was used to compare the demographic characteris-
tics among the two groups because not all quantitative
parameters have normal distributions, according to the
Shapiro–Wilk test. We used a paired Wilcoxon signed-
rank test within the groups. The results are expressed as
mean ± standard deviation (SD). Statistical significance
was set at P < 0.05.Results
There were no significant differences between the two
groups with respect to baseline demographic character-
istics, except for the dosage of DA and ERI, which were
higher in the DPP4+ group before treatment as shown
in Table 1. However, these differences were not signifi-
cantly different (P > 0.05).
After administration of linagliptin, the dosage of DA
and ERI decreased significantly (P < 0.05, Wilcoxon
signed-rank test). The dosage of DA decreased from a
mean (±SD) of 23.9 ± 21.2 to 11.3 ± 9.7 (μg/week), and
ERI decreased from 2.3 ± 2.1 to 1.0 ± 0.9 (Table 2).
Table 2 Change of parameters
Before treatment Post treatment Wilcoxon signed-rank test
Dosage of DA 23.9 ± 21.2 11.3 ± 9.7 P < 0.05
ERI 2.27 ± 2.08 1.04 ± 0.90 P < 0.05
Hb 10.8 ± 0.6 11.4 ± 0.9 NS
hs-CRP 5335 ± 6495 2568 ± 4059 NS
TSAT 24.2 ± 6.5 31.9 ± 11.0 NS
Ferritin 264.7 ± 334.6 249.8 ± 224.2 NS
Albumin 3.6 ± 0.4 3.6 ± 0.3 NS
WBC 5789 ± 1282 5687 ± 2121 NS
Plt 15.6 ± 6.4 15.2 ± 6.1 NS
DA darbepoetin alfa, ERI erythropoiesis-stimulating agent-resistant index, Hb hemoglobin, TSAT transferrin saturation, WBC white blood cells count, Plt platelet count
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count, platelet count, ferritin, and TSAT level were not
significantly different. There were no differences in Hs-
CRP level.
In contrast to the DPP4+ group, the dosage of DA and
ERI in the DPP4− group did not decrease significantly
after treatment with insulin (Figs. 1 and 2).
Discussion
DPP4 inhibitors selectively block DPP4, increase the ac-
tivity of glucagon-like peptide-1 (GLP-1), stimulate insu-
lin secretion, and inhibit glucagon secretion. The sole
use of a DPP4 inhibitor is considered to rarely induce
hypoglycemia because its plasma glucose-lowering effect
is dependent on the plasma glucose level. Additionally,
DPP4 inhibitors improve glycemic control without in-
creasing body weight [1]. Based on these characteristics,
a DPP4 inhibitor is very useful for diabetic patients on
hemodialysis. Linagliptin is mainly excreted from the bodyFig. 1 Change in dosage of darbepoetin alfaunchanged via fecal and renal excretion [8]. Janet et al. re-
ported that in patients with T2DM and severe renal
impairment, linagliptin provided clinically meaningful im-
provements in glycemic control with very low risk of
severe hypoglycemia, stable body weight, and no drug-
related renal failure [9]. Further, it has been reported that
linagliptin can be used at a regular dose in patients on
hemodialysis [10].
Recently the extra-pancreatic actions of DPP4 inhibi-
tors were indicated by many reports, including kidney
and cardiovascular protection, among other effects [2–
5]. Our study showed that DPP4 inhibitor linagliptin sig-
nificantly reduced the dosage of DA for T2DM patients
on hemodialysis with renal anemia and significantly de-
creased ERI as well.
The resistance to ESAs might be caused by inflamma-
tion, which has a negative effect on erythropoietin
receptors [11]. In our study hs-CRP, a marker of inflam-
mation, did not change significantly before or after
Fig. 2 Change in ESA-resistant index
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can cause erythropoietin-resistant anemia. However,
we also observed that TSAT and ferritin remained un-
changed throughout the treatment. Thus, we con-
cluded that DPP4 inhibitor linagliptin can reduce the
dosage of ESA without affecting iron metabolism or
inflammation.
A previous study by Broxmeyer showed that DPP4
cleaved within the N-termini of the CSFs, GM-CSF, G-
CSF, interleukin-3, and erythropoietin and decreased
their activity. Dpp4 knockout or DPP4 inhibition en-
hanced CSF activities both in vitro and in vivo. The re-
duced activity of DPP4-truncated versus full-length
human GM-CSF was mechanistically linked to effects on
receptor-binding affinity, induction of GM-CSF receptor
oligomerization, and signaling capacity. Hematopoiesis
in mice after radiation or chemotherapy was enhanced
in Dpp4−/− mice or mice receiving an orally active
DPP4 inhibitor. DPP4 inhibition enhanced engraftment
in mice without compromising hematopoietic stem cell
function, suggesting the potential clinical utility of this
approach [7].
Heather O’Leary et al. [6] suggested that DPP4 is a
protease that cleaves selected amino acids at the penulti-
mate N-terminal position and has the potential to alter
protein function. Recent reports on the number of pro-
teins that have DPP4 sites, and on how DPP4 truncation
may alter hematopoiesis based on the full protein length
versus the truncated state, have shown that DPP4 trun-
cation of CSFs alters their function and that the activity
of these CSFs can be enhanced when DPP4 activity is
inhibited. Thus, we speculate that the DPP4 inhibitor
can increase the concentration of erythropoietin by inhi-
biting the action of DPP4 on erythropoietin.In this study, the number of peripheral blood cells
(WBC, platelet) did not increase, because blood cells tend
to remain unchanged in hemodialysis patients. The level
of G-CSFs did not decrease either. Thus, we presume that
this was caused by the effect of the DPP4 inhibitor on
erythropoietin. However, we did not measure the serum
erythropoietin concentration because erythropoietin was
administrated to patients at the hemodialysis session.
Thus, we have merely speculated on the possible mechan-
ism behind the effect of DPP4 inhibitor on erythropoietin.
Terawaki et al. reported that linagliptin can decrease
serum levels of oxidized low-density lipoprotein in pa-
tients with T2DM undergoing hemodialysis independent
of its glucose-lowering effect [3]. Additionally, the GLP-
1 receptor agonist liraglutide has been demonstrated to
decrease oxidative stress independent of its glucose-
lowering effect [12]. We presume that as a result of the
reduction of oxidative stress, red blood cell survival may
have increased, thereby improving the ERI in our study.
Our study has some important limitations. This was
merely a pilot study, and thus, our study population was
small and the observation period was short. The patients
were not randomized to treatment, and there was no
blinding in place, which limits the strength of our results,
but we found an association between the DPP4 inhibitor
and erythropoietin. Confirmation of our findings is re-
quired in a large-cohort, randomized, double-blind study.
Conclusions
Based on the preliminary findings of the present study,
DPP4 inhibitors could be beneficial for patients with
T2DM undergoing hemodialysis. We conclude that the
DPP4 inhibitor linagliptin can reduce the dosage of ESA
in patients undergoing hemodialysis.
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